<DOC>
	<DOCNO>NCT00083226</DOCNO>
	<brief_summary>This phase II trial study well give doxorubicin together bortezomib work treat patient liver cancer . Drugs use chemotherapy , doxorubicin , work different way stop tumor cell divide stop grow die . Bortezomib may stop growth tumor cell block enzymes necessary growth . Giving doxorubicin together bortezomib may kill tumor cell .</brief_summary>
	<brief_title>Doxorubicin Bortezomib Treating Patients With Liver Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate tumor response rate patient hepatocellular carcinoma ( HCC ) . SECONDARY OBJECTIVES : I . To determine parameter antitumor effect include time tumor progression overall survival HCC patient treat bortezomib doxorubicin . II . To observe toxicity profile bortezomib doxorubicin patient hepatocellular carcinoma . III . To evaluate proteasome 20S inhibition tumor tissue ( include protein p21 , p27 , p53 , Bax Bcl-2 affect proteasome 26S ) compare clinical parameter use biopsy specimen obtain patient HCC treat bortezomib . ( Withdrawn 03-2007 ) IV . To measure phosphorylation IkB tumor tissue compare clinical parameter use biopsy specimen obtain patient HCC treat bortezomib . ( Withdrawn 03-2007 ) V. To evaluate effect bortezomib 26S proteasome activity peripheral white blood cell ( WBC 's ) patient serum . Direct measurement 26S proteasome activity well proteins affect proteasome 26S Nuclear factor kappa-B ( NF-kB ) analyze . ( Withdrawn 03-2007 ) OUTLINE : This multicenter study . Patients receive doxorubicin intravenously ( IV ) 5-15 minute day 1 8 . Patients also receive bortezomib IV 3-5 second day 1 , 4 , 8 , 11 . Treatment repeat every 21 day 12 course absence disease progression unacceptable toxicity . Patients disease progression may continue receive bortezomib alone absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year every 6 month 1 year . PROJECTED ACCRUAL : A total 40 patient accrue study within 13 month .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Patients must microscopically confirm hepatocellular carcinoma amenable curative resection ; patient isolate lesion one lobe liver , liver surgeon determine resectability ; central review require Patients must measurable disease determine Response Evaluation Criteria In Solid Tumors ( RECIST ) criterion , amenable biopsy ; patient mandate allow biopsy , even though important aspect clinical trial Patients history malignancy treat within past 5 year eligible ; history carcinomainsitu cervix , squamous cell cancer skin , basal cell cancer skin , previously treat allow ; others exclude recurrence disease may confuse response rate and/or survival endpoint Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Patients must prior systemic chemotherapy HCC ; patient antineoplastic nonmalignant disease , methotrexate rheumatoid arthritis , allow , provide patient agent least 4 week related toxicity resolve baseline Patients may prior embolization without chemotherapy ; patient chemoembolization eligible ; patient may radiofrequency ( RF ) ablation , cryosurgery ethanol injection ; patient must document progression involve lesion least one previously untreated lesion amenable biopsy Platelet count must &gt; = 100,000/mm^3 absence splenomegaly ; platelet count must &gt; = 75,000/mm^3 splenomegaly Absolute neutrophil count ( ANC ) must &gt; = 1,500/mm^3 absence splenomegaly ; ANC must = &lt; 1,000/mm^3 splenomegaly Alkaline phosphate ( ALT ) must = &lt; 5 x institutional upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) must = &lt; 5 x institutional ULN Bilirubin must = &lt; 2 mg/dl Patients may exhibit Child Pugh scale grade C cirrhosis Serum creatinine= &lt; 2.0 mg/dl All female childbearing potential must blood test urine study within 2 week prior registration rule pregnancy Women childbearing potential sexually active male strongly advise use accept effective method contraception Patients must know bleed diathesis , international normalize ratio ( INR ) &gt; 1.5 Partial thromboplastin time ( PTT ) &gt; 1.5 x institutional ULN ( require due biopsy portion study ) ; use vitamin K fresh frozen plasma correct value prior biopsy enrollment allow eligible Exclusion criterion : Patients baseline peripheral neuropathy &gt; grade 1 Patients history untreated malignancy HCC Patients prior use octreotide tamoxifen therapy HCC Patients know allergy boron , mannitol bortezomib Women pregnant breastfeeding ( due uncertain effect bortezomib develop fetus young infant ) Patients underlie medical condition precludes safe participation clinical trial Patients psychiatric illness continue substance abuse may impair ability provide inform consent prevent safe administration bortezomib Patients ejection fraction ( EF ) &lt; 50 % measure Echocardiography ( ECHO ) Multiple gated acquisition ( MUGA ) Patients verapamil switch alternative medication ( due interaction doxorubicin )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>doxorubicin</keyword>
	<keyword>doxorubicin hydrochloride</keyword>
	<keyword>bortezomib</keyword>
	<keyword>hepatocellular carcinoma</keyword>
</DOC>